Topical Drug Delivery and Percutaneous Absorption
Introduction
The skin's primary function as a barrier presents both challenges and opportunities for drug delivery. Understanding how drugs penetrate the stratum corneum—and how to enhance or control this penetration—is fundamental to dermatologic therapeutics.
Topical therapy offers unique advantages: targeted delivery, reduced systemic exposure, patient convenience, and the ability to directly visualize treatment effects. However, the skin's formidable barrier means that most molecules cannot penetrate effectively without careful formulation considerations.
Stratum Corneum as a Barrier
Barrier Architecture
The stratum corneum presents a 10-20 μm thick barrier consisting of corneocytes embedded in lipid lamellae—the "bricks and mortar" structure.
Loading diagram...
Physicochemical Requirements for Permeation
| Property | Optimal for Penetration | Rationale |
|---|
| Molecular weight | <500 Da | Diffuses through lipid matrix |
| Lipophilicity (log P) | 1-3 | Partitions into SC lipids |
| Melting point | Low (<200°C) | Correlates with solubility |
| Hydrogen bonding | Minimal | Reduces polar interactions |
| Ionization | Unionized preferred | Crosses lipid barriers |
Penetration Pathways
Three Routes Through the SC
Loading diagram...
Pathway Comparison
| Pathway | Surface Area | Drug Types | Importance |
|---|
| Intercellular | 95%+ of SC | Lipophilic, <500 Da | Primary route |
| Transcellular | 95%+ of SC | Small polar | Minor (high resistance) |
| Follicular | ~0.1% | Nanoparticles, large molecules | Significant for targeted delivery |
| Eccrine | ~0.1% | Minimal | Usually negligible |
Fick's Laws of Diffusion
First Law: Steady-State Flux
The rate of drug penetration is described by Fick's First Law:
J = (D × K × ΔC) / h
Where:
- J = Flux (mass/area/time)
- D = Diffusion coefficient in SC
- K = Partition coefficient (vehicle→SC)
- ΔC = Concentration gradient
- h = Diffusion path length
Loading diagram...
Practical Implications
| Parameter | How to Optimize | Clinical Application |
|---|
| Concentration (ΔC) | Use higher drug concentration | Higher potency formulations |
| Partition coefficient (K) | Match drug to SC lipophilicity | Prodrug strategies |
| Diffusion coefficient (D) | Reduce molecular size, lipophilicity | Drug design |
| Path length (h) | Tape stripping, exfoliation | Pre-treatment (rarely practical) |
Vehicle Effects on Penetration
Vehicle Components and Their Roles
Loading diagram...
Common Vehicle Types
| Vehicle | Characteristics | Best For | Penetration |
|---|
| Ointments | Lipophilic, occlusive | Dry conditions, thick plaques | ↑↑↑ |
| Creams | O/W or W/O emulsion | General use, cosmetically elegant | ↑↑ |
| Gels | Aqueous or alcohol-based | Hairy areas, acne | ↑↑ |
| Lotions | Low-viscosity emulsion | Large areas, hair-bearing | ↑ |
| Solutions | Simple solvent systems | Scalp, nails | ↑ |
| Foams | Aerosolized | Scalp, large areas | ↑↑ |
Rule of Occlusion
Occlusion dramatically increases penetration by:
- Increasing SC hydration (from ~15% to ~50% water)
- Reducing TEWL
- Increasing temperature
- Softening lipid lamellae
| Occlusion Method | Hydration Increase | Penetration Enhancement |
|---|
| Ointment base | 2-3× | 2-5× |
| Plastic wrap | 3-5× | 5-10× |
| Hydrocolloid dressing | 3-4× | 5-10× |
Chemical Penetration Enhancers
Mechanisms of Enhancement
Loading diagram...
Common Enhancers
| Enhancer | Mechanism | Enhancement | Safety |
|---|
| DMSO | Lipid/protein disruption | 10-100× | Irritation, odor |
| Azone | Lipid fluidization | 10-50× | Minimal irritation |
| Fatty acids (oleic) | Lipid disruption | 5-20× | Generally safe |
| Alcohols | Lipid extraction | 2-10× | Drying |
| Propylene glycol | Cosolvent, hydration | 2-5× | Sensitization possible |
| Terpenes (menthol, limonene) | Lipid fluidization | 5-20× | Generally well tolerated |
| Surfactants | Membrane disruption | 5-15× | Irritation risk |
Regional Variation in Absorption
Skin Site Differences
Absorption varies dramatically by anatomic site due to differences in SC thickness, follicular density, and vascularity.
Loading diagram...
Clinical Implications
| Site | Relative Absorption | Clinical Consideration |
|---|
| Scrotum/genitals | 40× | High systemic absorption risk |
| Face | 6× | Thinner SC; atrophy risk with steroids |
| Scalp | 4× | Hair follicle penetration |
| Axilla | 3.6× | Moist, occlusion effect |
| Forearm (ventral) | 1× (reference) | Standard testing site |
| Forearm (dorsal) | 0.8× | Slightly thicker SC |
| Palm | 0.5-0.8× | Thick SC |
| Sole | 0.1× | Very thick SC |
Special Considerations
Age-Related Differences
| Age Group | SC Characteristics | Absorption |
|---|
| Premature neonate | Immature barrier | ↑↑↑ |
| Term neonate | Maturing barrier | ↑↑ |
| Infant | Thin SC, high SA/weight | ↑ |
| Adult | Normal barrier | Baseline |
| Elderly | Thinner skin, ↓ lipids | ↑ |
Diseased Skin
| Condition | Barrier Effect | Absorption |
|---|
| Atopic dermatitis | Disrupted barrier | ↑↑ |
| Psoriasis | Parakeratosis | ↑ |
| Eczema | Inflammation, excoriation | ↑↑↑ |
| Burns | Barrier loss | ↑↑↑ |
| Ichthyosis | Thick SC (paradoxically) | Variable |
Topical Drug Formulation Strategies
Prodrug Approach
Loading diagram...
Examples of Dermatologic Prodrugs
| Prodrug | Active Drug | Conversion | Application |
|---|
| Valacyclovir (oral) | Acyclovir | Esterase | Herpes |
| Tretinoin | Retinoic acid | Oxidation | Acne, photoaging |
| Tazarotene | Tazarotenic acid | Esterase | Psoriasis, acne |
| Clobetasol propionate | Clobetasol | Esterase | Inflammation |
Drug Delivery Technologies
Emerging Approaches
Loading diagram...
Transdermal Drug Delivery Systems
| Drug | Patch System | Application |
|---|
| Nicotine | Matrix | Smoking cessation |
| Fentanyl | Reservoir | Pain management |
| Estradiol | Matrix | HRT |
| Testosterone | Matrix | Hypogonadism |
| Scopolamine | Reservoir | Motion sickness |
| Lidocaine | Matrix | Localized analgesia |
| Rotigotine | Matrix | Parkinson's disease |
Summary: Optimizing Topical Drug Delivery
Loading diagram...
Key Clinical Pearls
| Topic | Pearl |
|---|
| Rate-limiting barrier | Stratum corneum determines penetration (not dermis) |
| Lipophilicity sweet spot | Log P 1-3 optimal; too hydrophilic or lipophilic = poor penetration |
| Occlusion effect | 5-10× penetration increase; explains ointment potency |
| Regional variation | Scrotum absorbs 40× forearm; explains genital steroid atrophy risk |
| Diseased skin | Disrupted barrier = increased absorption; adjust dosing |
| Vehicle matters | Same drug, different vehicle = different clinical effect |
| Follicular route | Important for nanoparticle and biologics delivery |
Cross-References